Last reviewed · How we verify
APO-clonidine
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate.
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity by stimulating alpha-2 receptors in the brain and periphery. Used for Hypertension, Attention-deficit/hyperactivity disorder (ADHD).
At a glance
| Generic name | APO-clonidine |
|---|---|
| Sponsor | University Health Network, Toronto |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clonidine binds to alpha-2 adrenergic receptors in the central nervous system, decreasing the release of norepinephrine and reducing sympathetic outflow. This results in decreased peripheral vascular resistance and lower blood pressure. It is also used off-label for conditions involving sympathetic hyperactivity such as ADHD and opioid withdrawal.
Approved indications
- Hypertension
- Attention-deficit/hyperactivity disorder (off-label)
- Opioid withdrawal (off-label)
Common side effects
- Dry mouth
- Drowsiness
- Dizziness
- Constipation
- Rebound hypertension (upon discontinuation)
Key clinical trials
- Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |